TARO News and Press, Taro Pharmaceutical Industries Ltd. From 05/22/23

2023-05-22 17:35:17 ET Major earnings expected after the bell on Tuesday include: Agilent Technologies ( A ) Intuit ( INTU ) Palo Alto Networks ( PANW ) Toll Brothers ( TOL ) V.F. Corp. ( VFC ) For further details see: Notable earnings aft...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2023, after the close of market on Tuesday, May 23, 2023. The release will be accessible on Taro’s website at www.taro.com . About Taro...

Summary Taro Pharmaceutical's quarterly numbers came in with very thin growth at the operating and bottom-lines given the impact from settlement charges. Price erosion in its U.S. generics business continues to be a headwind. Question is, does the stock represent value at these comp...

Taro Pharmaceutical press release ( NYSE: TARO ): Q3 GAAP EPS of $0.19 misses by $0.68 . Revenue of $139.2M misses by $23.92M . For further details see: Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2022. Quarter ended December 31, 2022* Highlights ─ compared to December 31, 2021 ...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after the close of market on Tuesday, January 24, 2023. The release will be accessible on Taro’s website at www.taro.com . ...

Jazz Pharmaceuticals ( NASDAQ: JAZZ ) has filed a patent infringement lawsuit against several generic drugmakers for submitting abbreviated New Drug Applications (aNDAs) to the US FDA to market generic versions of Epidiolex (cannabidiol). Teva Pharmaceutical Industries ( NYSE: ...

Taro Pharmaceutical press release ( NYSE: TARO ): FQ2 Non-GAAP EPS of $0.66 misses by $0.18 . Revenue of $130.5M (-11.3% Y/Y) misses by $30.52M . Gross profit of $47.0M (36.0% of net sales) compared to $62.0M (47.0% of net sales). As of September 30, 2022, ...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2022. Quarter ended September 30, 2022* Highlights ─ compared to September 30...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2022, after the close of market on Thursday, October 27, 2022. The release will be accessible on Taro’s website at www....